Clinical research of Decitabine combined reduction FLAG regimen in the treatment of previously untreated high-risk and refractory or relapsed aged patients with acute myeloid leukemia

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR1800016691

Enrollment

Unknown

Registered

2018-06-17

Start date

2018-07-01

Completion date

Unknown

Last updated

2018-06-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute myeloid leukemia

Interventions

untreated high-risk group:Decitabine combined reduction FLAG regimen

refractory or relapsed group:Decitabine combined reduction FLAG regimen

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. 200 patients aged 55 to 75 years with acute myeloid leukemia; 2. Previously untreated high-risk and refractory or relapse aged patients; 3. ECOG-PS score=2.

Exclusion criteria

Exclusion criteria: 1. Treatment correlated AML; 2. patients with acute promyelocytic leukemia; 3. Suffered from other blood diseases at the same time; 4. With serious organ dysfunction, Liver and kidney function obviously abnormal; 5. Complicated with other malignant tumor; 6. Active heart disease (acute myocardial infarction, severe arrhythmia, congestive heart failure); 7. Complicated with serious infectious disease, AIDS; 8. Patients with epilepsy, dementia, and other mental disorders requiring medication cannot understand or follow the research plan.

Design outcomes

Primary

Measure	Time frame
marrow examination;blood routine examination;Adverse reactions;	—

Secondary

Measure	Time frame
overall survival;progression free survival;	—

Countries

China

Contacts

Public ContactZhao Mingfeng

Tianjin First Center Hospital

mingfengzhao@sina.com+86 13752640369

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026